Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence | Zendy

M. E. Falagas | Zendy; K. Giannopoulou | Zendy; Fotinie Ntziora | Zendy; Konstantinos Z. Vardakas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence

Author(s) -

M. E. Falagas,

K. Giannopoulou,

Fotinie Ntziora,

Konstantinos Z. Vardakas

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm137

Subject(s) - daptomycin , endocarditis , medicine , intensive care medicine , antibiotics , bacteremia , randomized controlled trial , gentamicin , clinical trial , vancomycin , staphylococcus aureus , microbiology and biotechnology , biology , bacteria , genetics

Endocarditis and bacteraemia are devastating infections with high mortality. Gram-positive cocci are the most commonly isolated pathogens. In an era of multidrug-resistant pathogens, the evaluation of new treatment options is important. Daptomycin is a cyclic lipopeptide that is active against most of these pathogens. Furthermore, it is a bactericidal antibiotic, a factor that is frequently considered in the choice of treatment of patients with bacteraemia and endocarditis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research